Skip to main content

Table 1 Mechanism of action and species specificity of translation inhibitors

From: The Plasmodium falciparum cytoplasmic translation apparatus: a promising therapeutic target not yet exploited by clinically approved anti-malarials

Compound Specificity Mechanism of action References
Bruceantin Eukaryotic (Pf cytoplasmic ribosomes) Inhibits initiation [16, 17]  
Verrucarin A Eukaryotic (Pf cytoplasmic ribosomes) Inhibits initiation, binds between P- & A- sites [13,14,15]  
Suramin Eukaryotic (Pf cytoplasmic ribosomes) Inhibits initation & elongation, multiple binding sites [18]  
Anisomycin Eukaryotic (Pf cytoplasmic ribosomes) Inhibits elongation, binds A-site [13, 17]
Cycloheximide Eukaryotic (Pf cytoplasmic ribosomes) Inhibits elongation, binds E-site [13]
Homoharringtonine Eukaryotic (Pf cytoplasmic ribosomes) Inhibits elongation on re-initiating ribosomes, binds A-site [13, 20]
Lactimidomycin Eukaryotic (Pf cytoplasmic ribosomes) Inhibits elongation, binds E-site [13]
Nagilactone C Eukaryotic (Pf cytoplasmic ribosomes) Inhibits elongation, binds A-site [13, 21]
Puromycin Pan-inhibitor tRNA mimetic [23, 24]
Halofuginone Eukaryotic Inhibits glutamyl-prolyl-tRNA synthetase [22]
Thiostrepton Prokaryotic (Pf mitochondrial & apicoplast ribosomes) Inhibits initiation & elongation [25,26,27,28,29,30,– 31]
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us